List of Excipients in API buprenorphine hydrochloride, naloxone hydrochloride
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing buprenorphine hydrochloride, naloxone hydrochloride
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Indivior Inc | BUPRENORPHINE AND NALOXONE | buprenorphine hydrochloride, naloxone hydrochloride | 0781-7216 | ACESULFAME POTASSIUM | |
| Indivior Inc | BUPRENORPHINE AND NALOXONE | buprenorphine hydrochloride, naloxone hydrochloride | 0781-7216 | CITRIC ACID MONOHYDRATE | |
| Indivior Inc | BUPRENORPHINE AND NALOXONE | buprenorphine hydrochloride, naloxone hydrochloride | 0781-7216 | FD&C YELLOW NO. 6 | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for buprenorphine hydrochloride, naloxone hydrochloride
Excipient focus: ACESULFAME POTASSIUM
buprenorphine hydrochloride, naloxone hydrochloride drug variants containing ACESULFAME POTASSIUM
buprenorphine hydrochloride, naloxone hydrochloride drug variants not containing ACESULFAME POTASSIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CITRIC ACID MONOHYDRATE
buprenorphine hydrochloride, naloxone hydrochloride drug variants containing CITRIC ACID MONOHYDRATE
buprenorphine hydrochloride, naloxone hydrochloride drug variants not containing CITRIC ACID MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C YELLOW NO. 6
buprenorphine hydrochloride, naloxone hydrochloride drug variants containing FD&C YELLOW NO. 6
buprenorphine hydrochloride, naloxone hydrochloride drug variants not containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSES
buprenorphine hydrochloride, naloxone hydrochloride drug variants containing HYPROMELLOSES
buprenorphine hydrochloride, naloxone hydrochloride drug variants not containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MALTITOL
buprenorphine hydrochloride, naloxone hydrochloride drug variants containing MALTITOL
buprenorphine hydrochloride, naloxone hydrochloride drug variants not containing MALTITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
buprenorphine hydrochloride, naloxone hydrochloride drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Indivior Inc | buprenorphine hydrochloride, naloxone hydrochloride | 0781-7216 |
| INDIVIOR INC | buprenorphine hydrochloride, naloxone hydrochloride | 12496-1202 |
| >Company | >Ingredient | >NDC |
buprenorphine hydrochloride, naloxone hydrochloride drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Aidarex Pharmaceuticals LLC | buprenorphine hydrochloride, naloxone hydrochloride | 53217-328 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOLS
buprenorphine hydrochloride, naloxone hydrochloride drug variants containing POLYETHYLENE GLYCOLS
| Company | Ingredient | NDC |
|---|---|---|
| Aidarex Pharmaceuticals LLC | buprenorphine hydrochloride, naloxone hydrochloride | 53217-328 |
| >Company | >Ingredient | >NDC |
buprenorphine hydrochloride, naloxone hydrochloride drug variants not containing POLYETHYLENE GLYCOLS
| Company | Ingredient | NDC |
|---|---|---|
| Indivior Inc | buprenorphine hydrochloride, naloxone hydrochloride | 0781-7216 |
| INDIVIOR INC | buprenorphine hydrochloride, naloxone hydrochloride | 12496-1202 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM CITRATE
buprenorphine hydrochloride, naloxone hydrochloride drug variants containing SODIUM CITRATE
buprenorphine hydrochloride, naloxone hydrochloride drug variants not containing SODIUM CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
